Cellulose Or Derivative Patents (Class 424/480)
-
Patent number: 7771747Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.Type: GrantFiled: October 10, 2006Date of Patent: August 10, 2010Assignee: Orexo ABInventors: Anders Pettersson, Christer Nyström, Yvonne Håkansson
-
Patent number: 7771746Abstract: A method of improving bioavailability of ergot derivatives administered using sustained-release delivery systems includes combining an ergot derivative or mixture thereof with a pharmaceutically acceptable hydrophilic swelling agent or mixture thereof and one or more pharmaceutically acceptable excipients. The bioavailability of sustained-release formulations of the present invention is at least equal to the bioavailability of the ergot derivative or mixture thereof administered using a conventional delivery system. Sustained-release compositions that improve bioavailability are also provided. Methods and compositions according to the present invention may provide sustained-release characteristics while improving the bioavailability of ergot derivatives.Type: GrantFiled: November 19, 2004Date of Patent: August 10, 2010Assignee: Polichem SAInventor: Federico Mailland
-
Publication number: 20100189791Abstract: Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties.Type: ApplicationFiled: June 9, 2009Publication date: July 29, 2010Inventors: Muhammad Safadi, Daniella Licht, Rachel Cohen, Anton Frenkel, Marina Zholkovsky
-
Publication number: 20100183714Abstract: The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed.Type: ApplicationFiled: March 24, 2005Publication date: July 22, 2010Applicant: LEK PHARMACEUTICALS D.D.Inventors: Marija Bogataj, Ales Mrhar, Anton Lavric, Manica Cerne, Doris Tibaut, Anton Stalc, Uros Urleb, Tatjana Mateovic, Greta Cof, Janez Kerc, Rok Dreu, Fumio Yoneda, Shizuko Muraoka
-
Patent number: 7749537Abstract: A method of forming a tablet includes the steps of pre-blending an active pharmaceutical ingredient susceptible to tackiness and a blending additive with a first mixing effort to form a pre-blend mixture, wherein the first mixing effort and a second mixing effort, resulting from mixing at least one excipient with the pre-blend mixture, form a blend suitable for direct compression and compressing the blend to form the tablet. One way of achieving the first mixing effort is to pre-blend for an extended period of time. The method allows for directly compressing the blend without the need for a granulation step or roller compression. One such active pharmaceutical ingredient susceptible to tackiness is ibuprofen.Type: GrantFiled: October 1, 2007Date of Patent: July 6, 2010Assignee: SCOLR Pharma, Inc.Inventors: Michael Hite, Cathy Federici, Alan Brunelle, Stephen Turner
-
Publication number: 20100166861Abstract: The present disclosure provides a pharmaceutical composition for the treatment of hyperphosphatemia in mammals. The composition includes sevelamer and copovidone. The composition is provided in the form of a coated tablet having a compressed core. Also disclosed are methods for the manufacture of such tablets, and methods for treating hyperphosphatemia in mammalian patients using the disclosed compositions.Type: ApplicationFiled: December 29, 2008Publication date: July 1, 2010Inventor: Kelly Noel Lynch
-
Patent number: 7744904Abstract: A stable composition including botulinum neurotoxin and a cyclodextrin and a method of preserving botulinum neurotoxin and for producing a botulinum neurotoxin composition with improved stability properties in an efficient and economically advantageous manner. The invention seeks to alleviate the problems associated with rapid degradation or denaturation of botulinum neurotoxin by providing a novel composition that exhibits improved stability properties. The botulinum neurotoxin is preferably stabilized by forming a cyclodextrin inclusion complex.Type: GrantFiled: September 21, 2006Date of Patent: June 29, 2010Assignee: B.B. Scientific L.L.C.Inventors: Bal Ram Singh, Andrew M. Ress
-
Publication number: 20100159003Abstract: The present invention relates to a process for the preparation of a medicament containing vardenafil hydrochloride trihydrate in solid form, in which vardenafil hydrochloride trihydrate is processed with suitable pharmaceutical auxiliaries at a temperature of from approx. 20° C. to approx. 45° C.Type: ApplicationFiled: June 12, 2008Publication date: June 24, 2010Applicant: ratiopharm GmbHInventors: Yogesh S. Deshpande, Sandra Brueck, Julia Schulze Nahrup, Birgit Schnitter, Ganesh Gat, Javed Hussain
-
Patent number: 7740881Abstract: Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. of from about 12.5% to about 42.5% (by wt) opioid released after 1 hour, from about 25% to about 65% (by wt) opioid released after 2 hours, from about 45% to about 85% (by wt) opioid released after 4 hours, and greater than about 60% (by wt) opioid released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of said opioid analgesic obtained in-vivo occurs from about 2 to about 8 hours after administration of the dosage form.Type: GrantFiled: July 24, 2000Date of Patent: June 22, 2010Assignee: Purdue Pharma LPInventors: Richard Sackler, Robert Kaiko, Paul Goldenheim
-
Publication number: 20100136111Abstract: The present invention relates to pharmaceutical compositions of diclofenac or pharmaceutically acceptable salts thereof and misoprostol or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparations of such compositions.Type: ApplicationFiled: March 25, 2008Publication date: June 3, 2010Inventors: Ramakant Gundu, Girish Kumar Jain, Murali Narayanan, Rahul Dabre, Mandar Kodgule
-
Publication number: 20100119602Abstract: The present invention is generally directed to compositions and formulations that can be used for the treatment of diseases such as End Stage Renal Disease (“ESRD”) and Chronic Renal Insufficiency (“CRI”). Specifically, it is directed to lanthanum-based compounds that bind phosphate and that can be formulated to provide for a reduced pill burden relative to other phosphate binders. In a formulation aspect of the present invention, a formulation is provided the includes a lanthanum-based, phosphate binder. The formulation is typically characterized in that in may be swallowed without chewing. Formulations of the present invention, along with a lanthanum-based compound, may optionally include the following: mass diluting agents; binders; coatings; compression/encapsulation aids; disintegrants; lubricants; plasticizers; slip/anti-electrostatic agents; powder lubricants; and, sweeteners. Where the formulation is in the form of a tablet, it typically has a volume between 0.3 cm3 and 1.2 cm3, preferably between 0.Type: ApplicationFiled: December 17, 2009Publication date: May 13, 2010Applicant: SPECTRUM PHARMACEUTICALS, INC.Inventors: Rudi E. Moerck, Alan J. Gotcher
-
Publication number: 20100112049Abstract: Pharmaceutical compositions comprising micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, wherein said compositions contain an amount of fenofibrate greater than or equal to 60% by weight and methods of producing fenofibrate compositions.Type: ApplicationFiled: January 13, 2010Publication date: May 6, 2010Applicant: ETHYPHARMInventors: Bruno Criere, Pascal Suplie, Philippe Chenevier, Pascal Oury, Keith S. Rotenberg, George Bobotas
-
Publication number: 20100074951Abstract: Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.Type: ApplicationFiled: October 30, 2007Publication date: March 25, 2010Applicant: HANALL PHARMACEUTICAL COMPANY, LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jae Woon Son
-
Publication number: 20100040678Abstract: The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition having a coating. In other aspects, rapid disintegrating compositions are provided. In a further aspect, a pharmaceutical composition which is free of sugar alcohols is provided. In another aspect, the invention provides a pharmaceutical composition comprising a coating comprising an S1P receptor modulator.Type: ApplicationFiled: September 25, 2007Publication date: February 18, 2010Inventors: Michael Ambuhl, Jutta Beyer, Begona Carreno-Gomez, Colleen Ruegger, Stephen Valazza
-
Publication number: 20090291138Abstract: A film-coated preparation having excellent storage stability, which contains a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof, having a film layer containing one or more film coating base agents selected from polyvinyl alcohol, sodium carboxymethyl cellulose and pullulan.Type: ApplicationFiled: December 6, 2007Publication date: November 26, 2009Applicants: DAIICHI SANKYO COMPANY, LIMITED, UBE INDUSTRIES, LTD.Inventors: Tomoyuki Watanabe, Kazuko Maeda
-
Publication number: 20090269403Abstract: Disclosed herein are oral dosage forms and methods of their use, in particular oral dosage systems for the delivery of drugs for use as a female oral contraceptive. In an embodiment, an oral dosage form includes a progestogen dispersed in an enteric polymer and an estrogen.Type: ApplicationFiled: April 23, 2009Publication date: October 29, 2009Inventors: Ze'ev Shaked, Justin R. Hughey
-
Publication number: 20090263482Abstract: Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine and also result in very few undesirable side effects.Type: ApplicationFiled: April 20, 2009Publication date: October 22, 2009Inventors: Vered Rosenberger, Brenda Kolatch, Linda Susan Marshall, Anna Hotovely-Salomon
-
Publication number: 20090252794Abstract: The present invention provides a novel tablet with improved tablet appearance and improved swallowability. The tablet contains a pharmaceutically acceptable anion exchange resin represented by colestimide as an active ingredient, and has a visibility-resolved tablet edge.Type: ApplicationFiled: August 9, 2007Publication date: October 8, 2009Inventors: Tetsuya Suzuki, Koji Tokutomi, Tatsuo Nomura, Chika Ohno, Tetsuro Yoshinari
-
Publication number: 20090238871Abstract: A pharmaceutical composition comprising an ester of 4-(1-hydroxy-1-methylethyl)-2 propyl-1-[[2?-(1H-tetrazol-5-yl)[1,1?-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid characterized in that when exposed to 75% relative humidity at 40° in open dish for one month the total amount of related substances does not increase more than 1% is described.Type: ApplicationFiled: May 2, 2007Publication date: September 24, 2009Applicant: LEK PHARMACEUTICALS D.D.Inventors: Matej Avanzo, Tanja Rozman Peterka, Igor Legen
-
Patent number: 7589051Abstract: A cationic, oxidized polysaccharide or derivative thereof that has a mean average molecular weight (Mw) having a lower limit of 50,000 and an upper limit of 1,000,000 and an aldehyde functionality content of at least 0.001 meq/gram is used in personal care and household care compositions. This cationic, oxidized polysaccharide is prepared in continuous or batch processes using hydrolytic reagents, oxidizing reagents, or combination of hydrolytic reagents and oxidizing reagents. Personal care or household care compositions are prepared by adding the cationic, oxidized polysaccharide to a personal care or household composition containing at least one active ingredient other than the cationic, oxidized polysaccharide of this invention.Type: GrantFiled: April 8, 2004Date of Patent: September 15, 2009Assignee: Hercules IncorporatedInventors: Paquita Erazo-Majewicz, Jashawant J. Modi, Zu-Feng Xu
-
Publication number: 20090202637Abstract: A pharmaceutical composition comprising a pharmaceutically active agent, a core, a coating comprising an inner film comprising cellulose acetate and hydroxypropylmethylcellulose in a ratio of cellulose acetate:hydroxypropylmethylcellulose of 80% to 99.5%:0.5% to 20% and an outer film comprising ethylcellulose and hydroxypropylcellulose in a ratio of ethylcellulose:hydroxypropylcellulose of 50% to 80%:20% to 50%.Type: ApplicationFiled: March 28, 2007Publication date: August 13, 2009Applicant: Novartis AGInventor: Petra Gisela Rigassi-Dietrich
-
Publication number: 20090181086Abstract: Disclosed are formulations which are designed to release rasagiline mesylate while maintaining specific pharmacokinetic properties.Type: ApplicationFiled: January 9, 2009Publication date: July 16, 2009Inventors: Muhammad Safadi, Daniella Licht, Rachel Cohen
-
Publication number: 20090175941Abstract: The invention describes a pharmaceutical composition of a slow-release preparation in the form of tablets for the treatment of vertigo of any genesis. A pharmaceutical composition is described that contains cinnarizine and dimenhydrinate, wherein the release of active ingredients is slowed down. For this purpose, the pharmaceutical composition additionally contains binding agent, slow-release agent and fillers.Type: ApplicationFiled: March 23, 2006Publication date: July 9, 2009Inventor: Gernot Francas
-
Patent number: 7553500Abstract: Pharmaceutical compositions having uniform drug distribution and potency utilizing laxofoxifene as an active ingredient and containing a silicon dioxide to reduce loss of the active ingredient during the manufacturing process and methods for manufacturing such compositions are disclosed.Type: GrantFiled: December 22, 2006Date of Patent: June 30, 2009Assignee: Pfizer IncInventor: Daniel S. Gierer
-
Patent number: 7537784Abstract: A modified-release tablet of bupropion hydrochloride comprising (i) a core comprising an effective amount of bupropion hydrochloride, a binder, a lubricant; and (ii) a control releasing coat surrounding said core; and (iii) a moisture barrier surrounding said control releasing coat, wherein the modified-release tablet is bioequivalent to Wellbutrin® or Zyban®/Wellbutrin®SR tablets.Type: GrantFiled: June 13, 2006Date of Patent: May 26, 2009Assignee: Biovail Laboratories International SRLInventors: Werner Oberegger, Okponanabofa Eradiri, Fang Zhou, Paul Maes
-
Publication number: 20090123543Abstract: A novel solid oral dosage form comprising a therapeutically effective amount of hydrophobic pharmacological active ingredient and at least one particle separating agent preferably selected from a class of wetting agents, prepared without or with minimum amount of a disintegrating agent. The hydrophobic pharmacological active ingredient active ingredient belongs to the class of angiotensin receptor blocking agents preferably is valsartan optionally in combination with hydrochlorothiazide. The active ingredient may also be a class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors preferably atorvastatin. The ratio of hydrophobic active ingredient to particle separating agent is about 20:1 to about 1:20. The process for the preparation of the novel solid oral dosage form comprises treating a hydrophobic active ingredient with at least one particle separating agent, and incorporating the treated hydrophobic active ingredient into a solid dosage form.Type: ApplicationFiled: January 2, 2007Publication date: May 14, 2009Applicant: Rubicon Research Private LimitedInventors: Pratibha S. Pilgaonkar, Maharukh T. Rustomjee, Anilkumar S. Gandhi, Paras R. Jain
-
Publication number: 20090117186Abstract: The invention at hand concerns trofosfamide containing film-coated tablets for oral application and a procedure for their production.Type: ApplicationFiled: February 10, 2006Publication date: May 7, 2009Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventor: Berthold Roessler
-
Patent number: 7510727Abstract: A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.Type: GrantFiled: December 23, 2003Date of Patent: March 31, 2009Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Mark Chasin, Hua-Pin Huang
-
Patent number: 7510728Abstract: In a solid pharmaceutical preparation containing 1) a basic medicinal component having an unpleasant taste; 2) a saccharide; 3) a polyanionic polymer; 4) a corrigent; and 5) carboxymethylcellulose, the unpleasant taste of the basic medicinal component having an unpleasant taste can be satisfactorily masked and excellent properties such as quick disintegration, appropriate preparation strength and high storage stability over a long period of time, etc., can be achieved. Further, a quickly disintegrating solid pharmaceutical preparation containing a medicinal component, a sugar alcohol and carboxymethylcellulose has excellent properties such as quick disintegration, appropriate preparation strength, high storage stability over a long period of time, etc.Type: GrantFiled: October 5, 2001Date of Patent: March 31, 2009Assignee: Takeda Pharmaceutical Company LimitedInventor: Masahiko Koike
-
Publication number: 20090053310Abstract: The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.Type: ApplicationFiled: July 3, 2006Publication date: February 26, 2009Inventors: Pratibha S. Pilgaonkar, Maharukh T. Rustomjee, Anilkumar S. Gandhi, Paras R. Jain, Atul A. Kelkar
-
Publication number: 20080317845Abstract: A duloxetine pellet formulation comprises: (i) a core including a desired amount of duloxetine; (ii) an enteric coating comprising hydroxypropylmethylcellulose phthalate (HPMCP) as an enteric polymer; and, optionally, (iii) a separating layer located between the core and the enteric coating, the separating layer including polyvinyl alcohol and a low molecular weight hydroxypropylmethylcellulose (HPMC).Type: ApplicationFiled: June 23, 2008Publication date: December 25, 2008Inventors: Peter Henry Robert Persicaner, Rahul Sareen
-
Publication number: 20080317858Abstract: Provided herein are intravenous and oral formulations of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide. Also provided are methods of making and using the formulations.Type: ApplicationFiled: June 24, 2008Publication date: December 25, 2008Inventors: Jinling Chen, Lian Rajewski, Aaron Schoeneman, Andrew M. Trammel, Kent Amsberry
-
Patent number: 7468194Abstract: Disclosed in certain embodiments is a method of treating infections of an interior part of the human or animal body, comprising administering to said interior body part, a pharmaceutical preparation comprising a particulate carrier and an effective amount of an agent selected from the group consisting of an antiseptic agent, a wound-healing promoting agent and a combination thereof, to treat an infection at said interior body part.Type: GrantFiled: May 25, 2000Date of Patent: December 23, 2008Assignee: Euro-Celtique, S.A.Inventors: Wolfgang Fleischer, Karen Reimer
-
Publication number: 20080311204Abstract: An enteric formulation containing at least one benzimidazole compound, said formulation containing: a core containing at least one benzimidazole compound and at least one lipophilic antioxidant, and an enteric envelope protecting the core at least at a pH of 3 to 5, preferably at a pH of 1 to 5.Type: ApplicationFiled: August 25, 2008Publication date: December 18, 2008Inventors: Francis VANDERBIST, Antonio Sereno, Philippe Baudier, Arthur Deboeck
-
Publication number: 20080305169Abstract: [Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.Type: ApplicationFiled: May 24, 2007Publication date: December 11, 2008Applicant: Japan Tobacco Inc.Inventors: Kazuki Miki, Fuyuki Arimoto, Masaki Sunami
-
Publication number: 20080292697Abstract: The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 80% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 80% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.Type: ApplicationFiled: December 6, 2007Publication date: November 27, 2008Inventors: Joseph Tyler, John S. Peterson
-
Publication number: 20080286356Abstract: Pharmaceutical compositions for oral administration comprising terbinafine and a method for administering high dosages while minimizing effects associated with e.g. a high dosage load, e.g. coated tablets or multiparticulate formulations such as minitablets or pellets, e.g. in capsules.Type: ApplicationFiled: July 18, 2008Publication date: November 20, 2008Inventors: Rainer Alles, Dieter Becker, Jean-Daniel Bonny, Stefan Hirsch, Oskar Kalb, Ernst Ulrich Kolle, Friedrich Karl Mayer, Anton Stutz, Anthony Williams
-
Publication number: 20080274182Abstract: Coated tablets for the delivery of active ingredients to a user are provided. Such tablets include particular molecular weight-modified carboxymethylcellulose (CMC) coating materials either alone or in combination with other types of hydrocolloids, biogums, cellulose ethers, and the like. The utilization of such modified CMC products aids in the production of such coatings through the availability of larger amounts of base materials with lower amounts of water requiring evaporation therefrom. In such a manner, not only may dimensionally stable, non-tacky, salt tolerant, and quick dissolving edible coatings be produced, but the amount of time required for such manufacture is minimal when compared with traditional methods of production with -based materials.Type: ApplicationFiled: May 3, 2007Publication date: November 6, 2008Inventors: Regina Helena Alida Boekema, Henrica Wilhelmina Cornelia Vaessen-van Hoven, Anja Maria Christina Petronella
-
Patent number: 7431944Abstract: Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.Type: GrantFiled: June 10, 2003Date of Patent: October 7, 2008Assignee: Celgene CorporationInventors: Atul M. Mehta, Andrew L. Zeitlin, Maghsoud M. Dariani
-
Publication number: 20080233192Abstract: The present disclosure relates to tablets obtainable by compression of a mixture comprising at least 5% by weight of a diluent and granules which comprise a very slightly soluble drug, wherein the granules consist of a core of saccharose beads having (prior to coating) a mean particle size greater than 150? and a coating layer comprising the very slightly soluble drug and at least one film-forming substance of high-molecular weight, as well as a process for manufacturing such tablets wherein the granules consist of a core saccharose beads having (prior to coating) a mean particle size greater than 150? and a coating layer comprising the very slightly soluble drug and at least one film-forming substance of high-molecular weight for the manufacture of tablets by compression of a mixture comprising said granules and at least 5% by weight of a diluent.Type: ApplicationFiled: July 10, 2006Publication date: September 25, 2008Inventors: Jose Luis Fabregas Vidal, Nuria Garcia Gonzalez, Pere Guiro Coll, Antoni Masso Carbonell
-
Publication number: 20080213366Abstract: The present invention provides oral formulations of poorly bioavailable and/or poorly absorbable, and/or poorly water soluble therapeutic agents. The invention features pharmaceutical composition including a biopolymer, a therapeutic agent, for example an antimicrobial agent such as ceftriaxone, and an absorption enhancer, for example a polyoxyethylene alkyl ether absorption enhancer. Methods of making and using the pharmaceutical compositions is also described.Type: ApplicationFiled: April 27, 2006Publication date: September 4, 2008Applicant: Cubist Pharmaceuticals, IncInventors: Walter G. Gowan Jr, Dennis D. Keith, Sandra O'Connor
-
Publication number: 20080193533Abstract: A sugar-coated agent that includes a core, a film layer that mainly includes a film component, the outer surface of the core being coated with the film layer, a sugar coating layer that mainly includes a sugar coating component, the outside of the film layer being coated with the sugar coating layer, and a middle layer that includes a film component and a sugar coating component and is provided between the film layer and the sugar coating layer, wherein within the middle layer, the concentration of the sugar coating component at the interface between the middle layer and the sugar coating layer is higher than the concentration of the sugar coating component at the interface between the middle layer and the film layer.Type: ApplicationFiled: March 9, 2006Publication date: August 14, 2008Applicant: Taisho Pharmaceutical Co., Ltd.Inventors: Junichi Kishimoto, Reiko Tanaka
-
Publication number: 20080166407Abstract: Multifunctional, single, bilayer, and trilayer coated tablets for combination therapy are formed wherein the bioactive agents responsible for the therapeutic multifunctionality are present as a combination of a gastric acid-reducing agent, such as omeprazole and ranitidine, and at least one analgesic/anti-inflammatory agent, such as acetaminophen, naproxen sodium, ibuprofen, tolmetin, and aspirin.Type: ApplicationFiled: February 21, 2008Publication date: July 10, 2008Inventors: Shalaby W. Shalaby, Kenneth David Gray, Joel T. Corbett
-
Patent number: 7387791Abstract: This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration.Type: GrantFiled: July 13, 2004Date of Patent: June 17, 2008Assignee: Oradel Medical Ltd.Inventors: Guru V. Betageri, Milton B. Yatvin
-
Publication number: 20080138410Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from a swellable composition and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating comprising water insoluble polymer(s) and leachable component(s) is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.Type: ApplicationFiled: November 28, 2007Publication date: June 12, 2008Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Nitin Bhalachandra DHARMADHIKARI, Yashoraj Rupsinh Zala, Amarjit Singh
-
Publication number: 20080085314Abstract: A first, solid oral pharmaceutical composition includes an extended release acetaminophen, a non-steroidal anti-inflammatory drug, such as naproxen or ibuprofen, and a third drug capable of reducing gastric acid secretion, such as ranitidine or omeprazole. A second, solid oral pharmaceutical composition includes a non-steroidal anti-inflammatory drug and an agent for reducing gastric acid secretion.Type: ApplicationFiled: July 27, 2006Publication date: April 10, 2008Inventor: Shalaby W. Shalaby
-
Publication number: 20080050432Abstract: The present invention relates to a combined pharmaceutical formulation, which is such designed that the release of each ingredient may be controlled to a predetermined release rate by applying the principle of the so-called chronotherapy, where drugs are administered in such a way that the activities of the drugs are expressed at intervals. The formulation of the present invention comprises statin-based lipid-lowering agent and dihydropyridine-based calcium channel blocker that affects cytochrome P450 enzyme as active ingredients, and is such constituted that the release rates of the aforementioned ingredients are different, thus preventing antagonism and side effects, while maintaining the synergistic effect, which leads to the convenience in medication.Type: ApplicationFiled: April 5, 2007Publication date: February 28, 2008Inventors: Sung Soo Jun, Young Gwan Jo, Ja-Seong Koo, Jin Wook Kim, Ju-Bin Yim
-
Publication number: 20070254033Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.Type: ApplicationFiled: April 13, 2007Publication date: November 1, 2007Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
-
Patent number: 7276250Abstract: Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: July 3, 2002Date of Patent: October 2, 2007Assignee: Penwest Pharmaceuticals CompanyInventors: Anand R. Baichwal, Huai-Hung Kao, Troy W. McCall
-
Patent number: 7276253Abstract: The invention relates to a stable medicament for oral administration which comprises (a) a core which contains an active ingredient selected from Omeprazole, Lansoprazole and Pantoprazole, together with customary pharmaceutical adjuvants, (b) an intermediate layer applied onto the core, and (c) a gastric juice-resistant outer layer. The intermediate layer in (b) is formed as a reactive layer in which a gastric juice-resistant polymer layer material partially neutralized with alkali with cation exchange capacity is present. Further, a method for the production of the stable medicament is disclosed.Type: GrantFiled: August 11, 2006Date of Patent: October 2, 2007Assignee: AstraZeneca ABInventors: Gerd-Ulfert Heese, Herbert Jünger, Arnim Laicher, Claudio Lorck, Thomas Profitlich, Gerd Weiss